AUPH Stock Summary and Trading Ideas (Aurinia Pharmaceuticals - Common Shares | NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.

As of December 24, 2025, AUPH stock price climbed to $16.27 with 344,080 million shares trading.

AUPH has a beta of 0.21, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.01 to the broad based SPY ETF.

AUPH has a market cap of $2.15 billion. This is considered a Mid Cap stock.

Last quarter Aurinia Pharmaceuticals - Common Shares reported $73 million in Revenue and $.23 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.07.

In the last 3 years, AUPH traded as high as $16.54 and as low as $4.07.

The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, JSMD.

AUPH has outperformed the market in the last year with a price return of +81.8% while the SPY ETF gained +17.3%. AUPH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.2% and +4.8%, respectively, while the SPY returned +4.4% and +1.4%, respectively.

AUPH support price is $15.88 and resistance is $16.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.